Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ESRRA | P11474 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3591604 | 0.87 | RAB9A (0.44) | CHRNA7RAB9AESRRAP2RX7LMNA | |
| SCHEMBL3591258 | 0.81 | MAPK1 (0.45) | MAPK1CHRNA7RAB9ATAAR1HPGD | |
| SCHEMBL3599795 | 0.81 | HDAC6 (0.47) | RAB9AESRRAP2RX7HDAC6EPHX2 | |
| SCHEMBL3602594 | 0.78 | TSHR (0.57) | CHRNA7RAB9ALMNAEPHX2POLB | |
| SCHEMBL3600244 | 0.78 | GAA (0.58) | RAB9APOLBALOX15SMN1; SMN2 | |
| SCHEMBL18967138 | 0.77 | RAB9A (0.54) | RAB9ALMNAHPGDPOLBTSHR | |
| SCHEMBL3605305 | 0.77 | THRB (0.48) | RAB9ALMNAHPGDCNR1POLB | |
| SCHEMBL3598193 | 0.77 | LMNA (0.57) | LMNAHDAC6TSHRSMN1; SMN2 | |
| SCHEMBL3198672 | 0.75 | ATM (0.49) | CHRNA7RAB9ALMNAHPGDHDAC6 | |
| SCHEMBL3598310 | 0.74 | NPC1 (0.46) | MAPK1P2RX7LMNAHPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807704-B2 | Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 | CHEMOCENTRYX, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-20070275965-A1 | CXCR4 modulators | CHEMOCENTRYX, INC. (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275965-A1 | CXCR4 modulators | CXCL12, CXCR4, CXCR1 | MAPK1 1264/4885CHRNA7 1268/4885RAB9A 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.